TL;DR: The Centers for Medicare & Medicaid Services modified NCD 66, the National Coverage Determination governing Medicare hyperthermia for cancer treatment, effective January 9, 2026. Here's what billing teams need to know.
This update to the CMS hyperthermia cancer treatment coverage policy draws a hard line on what Medicare will and won't pay for. The policy does not list specific CPT or HCPCS codes in the source document — billing teams should rely on MAC-level guidance and internal charge capture to identify the right codes. If your practice bills for hyperthermia services or refers patients for radiation therapy combinations, read this before January 9, 2026.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Hyperthermia for Treatment of Cancer |
| Policy Code | NCD 66 |
| Change Type | Modified |
| Effective Date | 2026-01-09 |
| Impact Level | Medium |
| Specialties Affected | Radiation Oncology, Medical Oncology, Dermatology, Surgical Oncology |
| Key Action | Confirm all hyperthermia claims are paired with radiation therapy for covered cutaneous or subcutaneous malignancies — not chemotherapy — before billing. |
CMS Hyperthermia Cancer Coverage Criteria and Medical Necessity Requirements 2026
NCD 66 in the Medicare system covers local hyperthermia as a physicians' service. The definition matters here: local hyperthermia uses heat to make tumors more susceptible to cancer therapy. This is not a standalone treatment in Medicare's eyes — and the coverage policy makes that explicit.
For a hyperthermia service to meet medical necessity under this policy, three things must be true. First, the hyperthermia must be local. Second, it must be used in connection with radiation therapy. Third, the cancer being treated must be a primary or metastatic cutaneous or subcutaneous superficial malignancy.
That last criterion is narrow. Superficial skin cancers and subcutaneous tumors qualify. Deep tumors, visceral cancers, and systemic malignancies do not. If your documentation doesn't specify the superficial nature of the malignancy, your claim is exposed.
The CMS hyperthermia cancer treatment coverage policy does not mention prior authorization as a requirement at the national level. That said, your Medicare Administrative Contractor may have its own local coverage determination (LCD) that adds prior authorization requirements or documentation standards on top of this NCD. Check with your MAC before the effective date of January 9, 2026.
Whether hyperthermia is covered under Medicare comes down to one question: is it being used with radiation to treat a superficial malignancy? If the answer is anything other than a clear yes, coverage doesn't apply.
CMS Hyperthermia Exclusions and Non-Covered Indications
The exclusions here are plain and non-negotiable. Medicare will not cover local hyperthermia when used alone. It will not cover hyperthermia when used in connection with chemotherapy. Those are the two hard stops.
The standalone exclusion matters more than it might seem. Some practices use hyperthermia as a palliative measure or as a prep step before a broader treatment plan kicks in. If radiation therapy isn't part of the same treatment course, the claim won't hold.
The chemotherapy exclusion is equally firm. Hyperthermia combined with chemotherapy — regardless of the cancer type, regardless of the clinical rationale — is not a covered combination under this NCD. Bill it that way and you're looking at a claim denial.
The policy is silent on regional hyperthermia, whole-body hyperthermia, and interstitial or intracavitary hyperthermia. That silence means those modalities fall outside this NCD's coverage scope. If your MAC hasn't addressed them via LCD, treat them as non-covered until you get written guidance.
The real issue is documentation. If your records don't clearly show the radiation therapy connection and the specific malignancy type, you're leaving your reimbursement vulnerable regardless of what was clinically appropriate.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Local hyperthermia + radiation therapy for primary cutaneous malignancy | Covered | Not specified in NCD | Must document superficial, cutaneous nature of malignancy |
| Local hyperthermia + radiation therapy for metastatic cutaneous malignancy | Covered | Not specified in NCD | Metastatic to skin qualifies; verify documentation of superficial involvement |
| Local hyperthermia + radiation therapy for subcutaneous superficial malignancy | Covered | Not specified in NCD | Must document subcutaneous, superficial location |
| Local hyperthermia used alone (no radiation or chemotherapy) | Not Covered | Not specified in NCD | Excluded explicitly under NCD 66 |
| Local hyperthermia + chemotherapy (without radiation) | Not Covered | Not specified in NCD | Explicitly excluded regardless of cancer type |
| Regional, whole-body, or interstitial hyperthermia | Not Addressed | Not specified in NCD | Falls outside NCD 66 scope; check MAC LCD |
CMS Hyperthermia Billing Guidelines and Action Items 2026
The hyperthermia billing implications here are concrete. Act on each of these before January 9, 2026.
| # | Action Item |
|---|---|
| 1 | Audit your current hyperthermia claims for the radiation therapy linkage. Pull claims from the past 12 months where hyperthermia was billed. Verify each one has a corresponding radiation therapy service in the same treatment course. Any claim that can't show that linkage is a denial risk going forward. |
| 2 | Update your documentation templates before January 9, 2026. Your clinical notes need to capture three things explicitly: the modality is local hyperthermia, the co-treatment is radiation therapy (not chemotherapy), and the malignancy is cutaneous or subcutaneous and superficial. Vague language like "skin cancer" isn't enough — document the depth and location precisely. |
| 3 | Contact your MAC about applicable local coverage determinations. NCD 66 in the Medicare system sets the national floor, but your MAC may have an LCD that adds code-level requirements, documentation thresholds, or prior authorization triggers. Get that guidance in writing before the effective date. |
| 4 | Identify the correct CPT or HCPCS codes with your MAC or billing consultant. This coverage policy does not list specific codes. That gap is a problem for hyperthermia billing, because without explicit code guidance in the NCD, coding teams often go inconsistent. Your MAC's LCD or claims processing instructions are the authoritative source — find them and lock them into your charge capture. |
| 5 | Train your radiation oncology and oncology billing staff on the chemotherapy exclusion. This is the most likely source of claim denial in practices that treat complex cancer patients. If a patient's plan includes both radiation and chemotherapy, hyperthermia is only covered when paired with the radiation component. Document and bill accordingly — don't let bundled treatment notes blur that line. |
| 6 | Flag any hyperthermia use outside the covered indications for compliance review. Whole-body, regional, or interstitial hyperthermia services are not addressed by NCD 66. If your providers use those modalities, talk to your compliance officer before billing them to Medicare. This is not a situation to figure out retroactively. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hyperthermia Under NCD 66
Covered CPT and HCPCS Codes
The NCD 66 policy document does not list specific CPT or HCPCS codes. This is a known gap in the national policy — it means billing teams must get code-level guidance from their Medicare Administrative Contractor or the MAC's local coverage determination.
Do not assume codes from other payers or internal charge masters apply here without MAC validation. If your MAC has published an LCD for hyperthermia services, that document will contain the specific codes Medicare expects. Use those codes, and document that you confirmed them from the LCD.
Not Covered / Experimental Codes
No specific CPT or HCPCS codes are listed in the NCD for non-covered services. The exclusions are defined by clinical scenario — hyperthermia alone, or hyperthermia with chemotherapy — not by code. Any code billed in those clinical scenarios will be denied.
Key ICD-10-CM Diagnosis Codes
The NCD does not list specific ICD-10-CM codes. Covered diagnoses are those representing primary or metastatic cutaneous or subcutaneous superficial malignancies. Your coding team should select ICD-10-CM codes from the C43–C44 range (malignant melanoma and other malignant neoplasms of skin) and related subcutaneous malignancy codes, validated against your specific patient presentation and MAC guidance.
If you're not sure which ICD-10-CM codes your MAC expects for this coverage, that's a question for your coding consultant or MAC provider relations representative — not something to guess at.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.